Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지

Risk Factor for Recurrence in Completely Resected Stage IB Non-small Cell Lung Cancer

완전 절제된 IB기 비소세포폐암에서 수술 후 재발의 위험 인자

  • Seok, Yang-Ki (Department of Thoracic and Cardiovascular Surgery, Kyungpook National University Hospital) ;
  • Lee, Eung-Bae (Department of Thoracic and Cardiovascular Surgery, Kyungpook National University Hospital)
  • 석양기 (경북대학교병원 흉부외과) ;
  • 이응배 (경북대학교병원 흉부외과)
  • Published : 2007.10.05
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Complete surgical resection is the most effective treatment for stage IB non-small cell lung cancer (NSCLC). Recurrence accounts for the disappointing survival rates after resection. There has been renewed interest in adjuvant therapy after complete resection. Appropriate selection of effective adjuvant therapy will depend on the prognostic factors for recurrence. Material and Method: The study included 114 patients with completely resected stage IB NSCLC. The variables selected for the study were gender, age, the type of resection, cell type, the degree of differentiation, the tumor size and the presence of visceral pleura invasion. The Kaplan-Meier method was used to estimate the survival and disease-free survival rate. The results were compared using the log rank test. Multivariate analysis was performed by Cox's proportional hazard model. Two-sided p-valves < 0.05 were considered to be statistically significant. Result: The 3-year overall survival and the disease-free survival rates were 87.0% and 79.4%, respectively. The degree of differentiation showed a significant influence on disease-free survival according to the univariate analysis. According to the multivariate analysis, a poor grade of differentiation was a significant poor prognostic factor. Conclusion: These results demonstrate that poor differentiation may be a poor prognostic factor for patients with completely resected IB NSCLC. Therefore, the patients with a poor grade of differentiation may require adjuvant therapies.

배경: IB기 비소세포폐암의 가장 효과적인 치료는 완전 절제이나, 수술 후 재발이 생기면 생존율이 떨어진다. 최근 IB기 비소세포폐암의 완전 절제 후 시행하는 보조 요법에 대해 관심이 높아지고 있다. 적절한 보조 요법을 사용하기 위해서는 재발의 위험 인자를 아는 것이 중요하다. 대상 및 방법: 114명을 대상으로 연구하였으며, 환자의 성별, 나이, 수술 방법, 조직학적 유형, 분화의 정도, 종양의 크기, 장측 흉막 침범 유무 등과 재발과의 관계를 분석하였다. 생존율과 무재발률은 Kaplan-Meier 방법으로 구하였으며, log rank test로 단변량 분석을, Cox's proportional hazard model을 이용하여 다변량 분석을 하였다. p값이 0.05 미만인 경우에 통계학적으로 유의하다고 판정하였다. 결과: 3년 생존율 및 무재발률은 각각 87.0%, 79.4%였다. 단변량 분석에서 분화도가 통계학적으로 의미가 있었으며, 다변량 분석에서도 저분화의 경우가 예후가 좋지 않았다. 결론: 완전 절제된 IB기 비소세포폐암 환자에서 저분화도가 재발과 연관된 인자이므로 수술 후 보조 요법이 필요할 것으로 기대된다.

Keywords

References

  1. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7 https://doi.org/10.1378/chest.111.6_Supplement.111S
  2. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-9 https://doi.org/10.1016/S0022-5223(95)70427-2
  3. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer. Chest 2002;122: 1037-57 https://doi.org/10.1378/chest.122.1.122
  4. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-21 https://doi.org/10.1056/NEJMoa032792
  5. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon J, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60 https://doi.org/10.1056/NEJMoa031644
  6. Lafitte JJ, Ribet ME, Prevost BM, Gosselin BH, Copin MC, Brichet AH. Postresection irradiation for T2N0M0 non-small cell carcinoma: a prospective, randomized study. Ann Thorac Surg 1996;62:830-4 https://doi.org/10.1016/S0003-4975(96)00507-3
  7. Ponn B, LoCicero III J, Daly BT. Surgical treatment of non-small cell lung cancer. In: Shields TW, Locicero III J, Ponn RB, Rusch VW. General thoracic surgery. 6th ed. Phiiladelphia: Wolters Kluver Co. 2005;1548-87
  8. Padilla J, Calvo V, Penalver JC, Sales G, Morcillo A. Surgical results and prognostic factors in early non-small cell lung cancer. Ann Thorac Surg 1997;63:324-6 https://doi.org/10.1016/S0003-4975(96)01034-X
  9. Naruke T, Tsuchiya R, Kondo H, Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 2001;71:1759-64 https://doi.org/10.1016/S0003-4975(00)02609-6
  10. Padilla J, Calvo V, Penalver JC, et al. Survival and risk model for stage IB non-small cell lung cancer. Lung Cancer 2002;36:43-8 https://doi.org/10.1016/S0169-5002(01)00450-0
  11. Carbone E, Asamura H, Takei H, et al. T2 tumors larger than five centimeters in diameter can be upgraded to T3 in non-small cell lung cancer. J Thorac Cardiovasc Surg 2001;122:907-12 https://doi.org/10.1067/mtc.2001.116949
  12. Takeda S, Fukai S, Komatsu H, Nemoto E, Nakamura K, Murakami M. Impact of large tumor size on survival after resection of pathologically node negative (pN0) non-small cell lung cancer. Ann Thorac Surg 2005;79: 1142-6 https://doi.org/10.1016/j.athoracsur.2004.09.062
  13. Jones DR, Daniel TM, Denlinger CE, Rundall BK, Smolkin ME, Wick MR. Stage IB nonsmall cell lung cancers: are they all the same? Ann Thorac Surg 2006; 81:1958-62 https://doi.org/10.1016/j.athoracsur.2005.12.054
  14. Cangir AK, Kutlay H, Akal M, Gungor A, Ozdemir N, Akay H. Prognostic value of tumor size in non-small cell lung cancer larger than five centimeters in diameter. Lung Cancer 2004;46:325-31 https://doi.org/10.1016/j.lungcan.2004.05.004
  15. Kang JH, Kim KD, Chung KY. Prognostic valve of visceral pleura invasion in non-small cell lung cancer. Eur J Cardiothorac Surg 2003;23:865-9 https://doi.org/10.1016/S1010-7940(03)00119-2
  16. Shimizu K, Yoshida J, Nagai K, et al. Visceral pleural invasion classification in non-small cell lung cancer: a proposal on the basis of outcome assessment. J Thorac Cardiovasc Surg 2004;127:1574-8 https://doi.org/10.1016/j.jtcvs.2003.11.017
  17. Ichinose Y, Hara N, Ohta M, et al. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer? J Thorac Cardiovasc Surg 1993;106:90-4